Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (ZOSTAVAX™) in Healthy Adults in India (V211-025)
PHASE3CompletedINTERVENTIONAL
Enrollment
250
Participants
Timeline
Start Date
October 31, 2012
Primary Completion Date
April 9, 2013
Study Completion Date
April 9, 2013
Conditions
Herpes ZosterShingles
Interventions
BIOLOGICAL
Zoster Vaccine Live
One approximately 0.65 mL injection subcutaneously on Day 1
All Listed Sponsors
lead
Merck Sharp & Dohme LLC
INDUSTRY
NCT01527370 - Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (ZOSTAVAX™) in Healthy Adults in India (V211-025) | Biotech Hunter | Biotech Hunter